Minerva Neurosciences Announces New Patent Application for MIN-117 Related to Broad Effect on Pain
November 28, 2018 08:00 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Nov. 28, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences to Present at Evercore ISI HealthCONx Conference on November 28, 2018
November 21, 2018 08:30 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Nov. 21, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat...
Minerva Neurosciences Announces Results of Dose Escalation Study Evaluating Roluperidone (MIN-101) Administered at Supra-Therapeutic Doses in Healthy Volunteers
November 19, 2018 08:00 ET
|
Minerva Neurosciences, Inc
Findings suggest expanded therapeutic window and significantly improved cardiovascular safety margin compared to formulation used in Phase 2b trial All doses tested up to 256 milligrams appear safe...
Minerva Neurosciences to Host Roluperidone Update and Key Opinion Leader Discussion of Negative Symptoms in CNS/Psychiatric Diseases on November 20, 2018
November 15, 2018 08:30 ET
|
Minerva Neurosciences, Inc
Minerva management to provide update on Phase 3 clinical trial with roluperidone and single-dose escalation study findings Additional topics to include review of recent BDNF data with roluperidone...
Minerva Neurosciences to Present at Jefferies London Healthcare Conference on November 14, 2018
November 07, 2018 08:30 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat...
Minerva Neurosciences Reports Third Quarter 2018 Financial Results and Business Updates
November 05, 2018 07:30 ET
|
Minerva Neurosciences, Inc
Data readouts from five ongoing late-stage trials expected in 2019 WALTHAM, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical...
Minerva Neurosciences to Report Third Quarter 2018 Financial Results and Business Updates on November 5, 2018
October 29, 2018 08:30 ET
|
Minerva Neurosciences, Inc
Management to host conference call WALTHAM, Mass., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the...
Minerva Neurosciences Announces Findings Showing Effect of Roluperidone on Brain-Derived Neurotrophic Factor (BDNF)
August 22, 2018 08:30 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Aug. 22, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Reports Second Quarter 2018 Financial Results and Business Updates
August 02, 2018 07:30 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences to Report Second Quarter 2018 Financial Results and Business Updates on August 2, 2018
July 26, 2018 08:30 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., July 26, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...